1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61D10EDA86797DDC985257A610072F432
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/novartis-long-term-brand-building-in-competitive-marketplace?opendocument
18
19opendocument
2034.229.151.87
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing Marketing Management Designing Marketing Strategies Product Positioning and Differentiation

Diovan Case Study: Long-Term Brand Building in The Competitive Antihypertensive Market

ID: 5222


Features:

20 Info Graphics

6 Data Graphics

50 Metrics

8 Narratives


Pages/Slides: 37


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Diovan Case Study: Long-Term Brand Building in the Competitive Antihypertensive Market"

STUDY OVERVIEW

Novartis' blood pressure treatment Diovan faced multiple challenges when it entered the crowded antihypertensive market. Diovan, a Angiotension Receptor Blocker (ARB), was the second drug launched in that class - ARB market leader Cozaar hit the market two years earlier. Also, Diovan entered the market with a weaker dosage. After a tepid launch that saw Diovan having trouble penetrating the crowded marketplace, Novartis leaders built a business case that gained senior leadership support for a long-term brand building strategy for Diovan. The plan they executed included tactics such as winning expanded dosing options, launching large comparative effectiveness studies, investing in expanded sales and marketing activities and seeking partnerships with key stakeholders to promote education.

These tactics - executed in stages over a 10-year period - helped increase Diovan's reach annually so that by 2002, the drug surpassed Cozaar as the #1 prescribed ARB. In 2010, Diovan hit $6.1 billion in sales, making it the best-selling drug in Novartis' history.

Using secondary research and interviews with a Diovan brand manager, Best Practices, LLC created this case study to highlight how to effectively execute a multi-pronged strategy to boost a brand's presence in a crowded market. Executives can use this study to understand Novartis' approach to long-term brand building in a competitive marketplace.

KEY TOPICS

  • Executive Summary
  • Efficacy Perception & Expanded Dosing Options Became Critical Themes in Building Brand Positioning
  • Ongoing Sales Investment & Expansion Raised Awareness Among Targeted Physicians
  • Large Patient Outcome & Comparative Effectiveness Studies Engaged Thought Leaders & Differentiated Diovan in a Crowded Market
  • Patient Support Programs Supported Portfolio & Focused on Increasing Patient Compliance
  • Partnerships with Key Stakeholders Promoted Disease State Awareness & Education
  • Appendix

METHODOLOGY

Insights were drawn from extensive secondary research and an interview with a Diovan Brand Manager.

Industries Profiled:
Pharmaceutical


Companies Profiled:
Novartis


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.